戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ckers (atenolol, metoprolol, propranolol, or nadolol).
2 receiving metoprolol compared to propranolol/nadolol.
3  contractility with and without atropine and nadolol.
4  are beta3-sparing, including propranolol or nadolol.
5 eatment with the beta-adrenergic antagonist, nadolol (0.5 mg/kg), but not by the alpha-antagonist phe
6 Propranolol (10 mg/kg, intraperitoneally) or nadolol (10 mg/kg, intraperitoneally) administered 30 mi
7 with metoprolol (a beta(1)-AR antagonist) or nadolol (a beta(1)- and beta(2)-AR antagonist), but were
8 ed group, acute responders were treated with nadolol and acute nonresponders with nadolol+nitrates.
9 ed 5-7 days after maximal tolerated doses of nadolol and nitrates.
10 rker and racemic mixtures of the antagonists nadolol and propranolol demonstrated that the immobilize
11                              Propranolol and nadolol are equally effective, whereas symptomatic patie
12 shortening effect compared to metoprolol and nadolol, especially in patients with prolonged QTc.
13 d trial of endoscopic variceal ligation plus nadolol in preventing recurrent variceal bleeding and se
14 ranolol (n = 134), metoprolol (n = 147), and nadolol (n = 101) were analyzed, excluding patients <1 y
15           The control group was treated with nadolol+nitrates+ligation.
16 ed with nadolol and acute nonresponders with nadolol+nitrates.
17                  (ii) Chronic treatment with nadolol or carvedilol significantly increased beta-AR de
18 e observed that: (i) The beta-AR antagonists nadolol or carvedilol, given as a single i.v. injection
19 evented by addition of the betaAR antagonist nadolol or exogenous IFN-gamma.
20 renergic receptor antagonists propranolol or nadolol or the alpha1- + beta1,2,3-adrenergic receptor a
21               Chronic nonresponders received nadolol+prazosin and had a third HVPG study.
22 ilar among the 4 beta-blockers, but in LQT2, nadolol provided the only significant risk reduction (ha
23 n LQTS, their efficacy differed by genotype; nadolol was the only beta-blocker associated with a sign
24 s for atenolol, metoprolol, propranolol, and nadolol were 0.71 (0.50 to 1.01), 0.70 (0.43 to 1.15) 0.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。